Scientific news

Cannabis researcher says close monitoring of impacts of legalisation critical

As legalisation finally becomes a reality, an Ontario-based cannabis researcher says careful monitoring of its impacts after October 17 is critical

What legal weed in Canada means for science

Opportunities abound to improve the cultivation of a once-forbidden plant

Zelda Therapeutics to focus on US and Australia clinical trials

A strategic review will see more focus on the largest global markets for medicinal cannabis

Teewinot announces new pharmaceutical subsidiary

Canalis is a drug discovery and development company that is using cannabinoids and their NCEs (New Chemical Entities) as small molecule libraries for identifying compounds with human therapeutic activity

Synthetic or plant-based cannabis for symptom relief in patients with cancer?

A distinction between synthetic cannabinoids and whole-plant or plant-based cannabis is warranted, especially in regard to which type of cannabis is covered in clinical practice and research

Sundial signs deal with University of Saskatchewan to research effect of cannabis on dementia

The medicinal cannabis company has signed a three-year memorandum of understanding with the university to look into whether cannabis could have a positive effect on the aging brain

Project CBD releases educational primer on cannabinoid-drug interactions

Given the increasing acceptance and prevalence of cannabis as a therapeutic option, it’s important for physicians and patients to understand how various cannabis components interact with commonly consumed pharmaceuticals

Study finds cannabis increases pain tolerance

A new study found that cannabinoids may not reduce pain as much as they increase our tolerance of pain and make it less unpleasant

Cannabinoid drugs make pain feel 'less unpleasant, more tolerable'

Researchers have determined that cannabinoid drugs do not appear to reduce the intensity of experimental pain, but may make pain feel less unpleasant and more tolerable

Why Cronos Group's partnership to produce cultured cannabinoids could be a big deal

Earlier this month, Cronos Group entered into a partnership with Ginkgo Bioworks to develop cannabinoids using organism design and development technology